Table 4.
Development of TAA-specific T cells during therapy
| Any TAA responses | Any TAA responses post-vaccination (vs pre-vaccination) |
| PSA | 11/17 (65%) |
| MUC-1 | 17/17 (100%) |
| Brachyury | 14/16 (88%) |
| 1 antigen | 1/17 (6%) |
| 2 antigens | 8/17 (47%) |
| 3 antigens | 8/17 (47%) |
| ≥2 antigens | 16/17 (94%) |
| Any antigen | 17/17 (100%) |
| Multifunctional TAA responses | >3× post vs pre (or if no pre, >100/1×106 cells at post) | >10× post vs pre (or if no pre, >1000/1×106 cells at post) | >100x post vs pre (or if no pre, >5000/1×106 cells at post) |
| PSA | 9/17 (53%) | 6/17 (35%) | 3/17 (18%) |
| MUC-1 | 13/17 (76%) | 8/17 (47%) | 4/17 (23%) |
| Brachyury | 13/16 (81%) | 4/16 (25%) | 1/16 (6%) |
| Any antigen | 16/17 (94%) | 13/17 (76%) | 8/17 (47%) |
Frequency of patients developing any CD4+ or CD8+ T-cell responses post-vaccinination (vs pre-vaccination). The absolute number of T cells producing IFN-γ, TNFα, or IL-2 or positive for the degranulation marker CD107a per 1×106 peripheral blood mononuclear cells plated at the start of the stimulation assay was calculated. Following subtraction of background and any signal obtained prior to vaccination, a patient was scored as developing any TAA-specific T-cell response during therapy if the patient had >250 CD4+ or CD8+ T cells that produced IFN-γ, TNFα, or IL-2 or were positive for CD107a at the end of the stimulation assay per 1×106 cells that were plated at the start of the assay.
Frequency of patients developing polyfunctional TAA responses (CD4+ and CD8+ T cells expressing two or more of the following: IFN-γ, TNFα, IL-2, or CD107a) post-vaccination versus pre-vaccination. The frequency of patients developing a >3-fold, >10-fold, and >100-fold increase in multifunctional TAA-specific T cells after (vs before) vaccination is indicated.
IFN-γ, interferon-γ; IL-2, interleukin-2; PSA, prostate-specific antigen; TAA, tumor-associated antigen; TNFα, tumor necrosis factor-α.